Bullish case
$330 to $360
More likely if Ligand continues to sign new licensing deals, Captisol revenue stabilizes, milestone payments flow predictably, and the market awards a 25-30x forward multiple on 12-15% EPS growth.
Ligand Pharmaceuticals Incorporated research snapshot
LGND AI Stock Analysis
LGND AI stock analysis currently reads Ligand Pharmaceuticals Incorporated as a small-cap biopharma royalty aggregator with an asset-light model, high gross margins, lumpy revenue from milestone payments, a strong recent stock run-up, and a premium valuation that already reflects execution optimism. At the July 10, 2026 close, LGND traded near $316.24 with a market capitalization around $6.34 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$316.24
Market cap
$6.34 billion
AI score
72 / 100
Rating
High-margin royalty aggregator, premium valuation
Trend status
Strong uptrend with elevated valuation risk
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- B-level information richness. LGND has public filings, quarterly reports, and analyst coverage from 6 firms, but its small market cap and unusual royalty-aggregator model mean less coverage depth than large-cap biopharma, and some quarterly data requires reconciling lumpy milestone payments.
- bias Check
- The main AI bias risk is extrapolating the recent price momentum (67% YTD, 153% 1-year) forward, and over-weighting optimistic analyst targets (high $388) while under-weighting the convertible debt dilution, revenue lumpiness, and premium multiple.
- ai Confidence
- High for filings, revenue mix, market cap math, analyst consensus, and technical snapshots. Medium for forward valuation because LGND revenue is dependent on partner drug performance, milestone timing, and new licensing deals that are hard to model quarterly.
- investment Certainty
- Low-medium. The business quality is real and improving, but the current price already reflects strong expectations, and the margin of safety at 42x trailing earnings is thin for a small-cap royalty model.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ligand owns royalty rights to about 90 pharmaceutical products across immunology, oncology, infectious disease, CNS, and kidney disease, generating high-margin recurring revenue with only 47 employees. | High |
| Moat | The moat comes from its Captisol and NITRICI formulation platforms, contractual royalty structures, and a diversified portfolio of partnered drugs that create switching costs for licensees. | Medium |
| Management | CEO Todd Davis and the team have shifted Ligand from drug development to a capital-efficient royalty aggregator, but the recent $625M convertible note offering adds dilution risk and signals large capital needs. | Medium |
| Financial trend | TTM revenue reached about $274.48 million with a profit margin near 56%. Q1 2026 showed a net loss of $13.34M due to debt-offering charges, while prior quarters showed strong profitability and milestone-driven revenue. | Medium-high |
| Valuation | At 42x trailing EPS and 24x sales, LGND trades at a premium to the biotech sector median. The forward P/E of 36x still prices in above-average growth and deal flow. | Medium-high |
| Technical trend | The stock is near its all-time high of $326.63 set on July 8, 2026. The 6-month return was about 58% and the 1-year return was about 160%, signaling a strong uptrend. | Medium |
| Risk level | Main risks are revenue lumpiness, royalty concentration, convertible debt dilution, partner-dependent cash flows, small-cap volatility, and valuation risk at 42x earnings. | Medium-high |
| AI confidence | High for descriptive research and verified calculations. Lower for future price outcomes because LGND is driven by milestone payments, licensing deals, and partner drug performance that are hard to forecast. | High data confidence |
| Investment certainty | Low-medium certainty. LGND has a differentiated model, strong margins, and momentum, but the current price embeds high expectations and the margin of safety is limited. | Low-medium |
LGND AI stock forecast
LGND AI Stock Forecast Scenarios
The LGND AI stock forecast uses scenario math around the $316.24 quote and $7.53 TTM EPS. The three-year framework produced a bearish area near $123, a base area near $221, and a bullish area near $344, depending on EPS growth and assigned multiples.
Base case
$210 to $230
More likely if EPS compounds around 8-10% annually, partner drug performance is steady but unspectacular, and the market applies a 20-22x multiple consistent with a small-cap specialty pharma company.
Bearish case
$115 to $130
More likely if key partner drugs face competition or regulatory setbacks, convertible debt dilutes EPS significantly, revenue misses estimates, or the market compresses the multiple toward 12-15x.
LGND AI technical analysis
LGND AI Technical Analysis
LGND AI technical analysis shows strong momentum with the stock near its all-time high of $326.63 set on July 8, 2026. The stock has rallied 67% YTD and 160% over the past year, supported by solid fundamentals and analyst upgrades.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $316.24 | Quote snapshot from Nasdaq at the July 10, 2026 close, used for market cap math at the July 12, 2026 cutoff. |
| All-time high | $326.63 | Set on July 8, 2026, near the upper end of the current uptrend. |
| Near support | $290 to $300 | The area around the 20-day moving average and prior resistance-turned-support zone from late June 2026. |
| Key resistance | $326 to $330 | The all-time high zone represents immediate resistance. A clean breakout above $330 would open the path higher. |
| 52-week low | $120.68 | Set in July 2025, the stock has more than doubled from this level. |
| Momentum | Strong upward momentum | YTD return of 67.26% and 1-year return of about 160% indicate a powerful uptrend. |
| Volume | About 147,000 to 335,000 daily shares | Trading volume is moderate for a small-cap stock. Average volume is about 335,000 shares. |
| Volatility | Moderate-high small-cap biotech volatility | Expect larger moves around licensing deal announcements, earnings, and clinical data for partner drugs. |
| Invalidation | Close below $290, then $250 | A decisive break below $290 would weaken the short-term bullish setup. A break below $250 would suggest a deeper correction. |
LGND AI trading strategy
LGND AI Trading Strategy Framework
The LGND AI trading strategy is a rules-based research framework for a small-cap biopharma royalty aggregator in a strong uptrend but at premium valuation. It is not personal advice and should be paired with live quotes, filings, and event-risk monitoring.
Trend-following setup
Watch for LGND to hold above the $290 support zone and clear the $326 all-time high resistance with above-average volume and positive catalyst news.
A close below $290 or a failed breakout above $326 with declining volume should invalidate the trend-following setup.
Mean-reversion setup
If LGND pulls back toward $290-$300 on normal volatility without a fundamental thesis break, compare entry with partner drug performance, cash position, and recent deal flow.
Do not average down without a defined loss limit because small-cap biotech stocks can gap down on adverse news about partner products.
Catalyst monitor
Track licensing announcements, partner drug regulatory milestones, quarterly revenue mix between royalties and milestones, cash burn, and the impact of the convertible note issuance.
Reduce exposure if the company needs to issue additional equity or if a key partner drug faces a clinical or regulatory setback.
Investment research summary
Four-master Research Compression
Business essence
Ligand converts pharmaceutical royalty rights, formulation technology licensing, and milestone payments into high-margin recurring revenue with an unusually lean operational structure of 47 employees.
Moat
The moat is strongest where Captisol formulation technology creates technical switching costs for licensees and where contractual royalty streams provide recurring revenue independent of Ligand operational execution. It narrows if partner drugs face competition, patent expiry, or clinical failure.
Munger risk inversion
The thesis fails if revenue becomes too dependent on a single partner product, if convertible debt leads to significant dilution, if new deal flow dries up, or if the small-cap structure amplifies any negative surprise into a severe multiple compression.
Management
Management has successfully transitioned Ligand from a traditional drug developer to a capital-efficient royalty aggregator. The recent $625M convertible note offering signals aggressive growth ambitions but also adds financial complexity and dilution risk.
Industry trend
The biopharma industry benefits from aging populations, rising healthcare spending, and continued innovation. Ligand model of partnering with larger firms and collecting royalties is a proven approach that reduces operational risk but depends on partner execution.
Valuation and margin of safety
LGND is not priced as a value stock. At 42x trailing earnings, the market is pricing in continued deal flow, steady royalty growth, and successful capital deployment. Margin of safety depends on whether the company can deliver the growth implied by the multiple.
Source-backed data
LGND Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LGND price | $316.24 | Yahoo Finance and Nasdaq quote snapshot | July 10, 2026 |
| Market capitalization | $6.34 billion, verified as $316.24 x 20.04 million shares | financial_rigor.py market cap verification | July 10, 2026 |
| TTM revenue | $274.48 million (consensus of sources) | Yahoo Finance, TradingView, and Google Finance cross-check | July 10, 2026 |
| TTM net income | $153.56 million (Yahoo TTM). FY2025 net income was $124.45 million (TradingView). Variation due to milestone timing. | Yahoo Finance and TradingView cross-check | July 10, 2026 |
| EPS (TTM) | $7.53 | Yahoo Finance and Google Finance | July 10, 2026 |
| Cash and equivalents | $779.4 million (most recent quarter) | Yahoo Finance key statistics | July 10, 2026 |
| Debt-to-equity | 45.32% | Yahoo Finance | July 10, 2026 |
| Levered free cash flow (TTM) | $142.11 million | Yahoo Finance | July 10, 2026 |
| Valuation check | 42.0x trailing P/E, 36.2x forward P/E, 24.1x price/sales, 6.5x price/book | financial_rigor.py valuation verification and Yahoo Finance | July 10, 2026 |
| Analyst consensus | Buy (6 analysts, all Buy/Strong Buy). Average target $310.60, high $388.00 (BofA), low $262.00 (RBC) | Google Finance analyst ratings | July 10, 2026 |
| Shares outstanding | 20.04 million | Yahoo Finance and Google Finance | July 10, 2026 |
| Convertible notes offering | $625 million of 0% convertible senior notes due 2031, priced in June 2026 | GlobeNewswire via Yahoo Finance | June 2026 |
Frequently Asked Questions
Read the ABBV AI stock analysisView VRTX AI stock forecastExplore BNTX AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen biotech stocks with Pineify
This LGND AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, licensing deals, clinical data, convertible note developments, market moves, or macro conditions.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it